TMEM135 is a membrane-associated organelle regulator that links mitochondrial dynamics and peroxisomal dysfunction. Evidence in mammalian systems indicates that TMEM135 helps coordinate mitochondrial fission, peroxisome-related lipid processing, and energetic adaptation under cellular stress.
In NeuroWiki terms, TMEM135 is best viewed as a network-modulating protein rather than a primary monogenic driver of classic neurodegenerative syndromes. Current human disease associations are strongest in retina/hearing phenotypes and metabolic stress biology, while neurodegeneration relevance is mechanistically plausible but still early-stage.[1][2]
TMEM135 is a multi-pass transmembrane protein localized to mitochondrial and peroxisome-associated membranes, where it influences organelle morphology and substrate flux.[3][4] Unlike catalytic enzymes, TMEM135 appears to function as an organizational or trafficking regulator inside the mitochondrial-peroxisome axis.[3:1][5]
Key context:
This biology makes TMEM135 relevant to disorders where chronic mitochondrial stress and lipid dysregulation amplify neuronal vulnerability.
Experimental data support a role for TMEM135 in mitochondrial fission-state control and adaptation during energetic demand.[3:3][1:2] This places TMEM135 upstream of mitochondrial quality-control logic that also intersects with DRP1, mitophagy, and oxidative stress buffering pathways.[8][9]
TMEM135 participates in peroxisome-linked lipid handling, including pathways relevant to very-long-chain fatty acids and docosahexaenoic acid (DHA) balance in some systems.[5:1][6:1] Because neuronal membranes are lipid-intensive and synaptic function is lipid-sensitive, disruption in peroxisomal support can have downstream CNS effects even when the initial defect is metabolic.[6:2][10]
TMEM135 appears to act at an interface where mitochondrial and peroxisomal stress responses are coordinated.[3:4][5:2] This systems role may be more important than a single molecular interaction, particularly in aging tissues where cumulative oxidative and energetic stress rises.
Mitochondrial dysfunction is a convergent mechanism across Alzheimer's Disease, Parkinson's Disease, and related tau/synuclein disorders.[8:1][9:1][11] TMEM135 does not yet have strong direct causal evidence in these diseases, but its mechanistic position is relevant because it influences the same organelle-control layer that fails in vulnerable neurons.
Practical interpretation:
Several TMEM135 studies show retinal pathology and progressive hearing phenotypes in mutation models.[2:2][7:1] These findings are valuable for neurodegeneration research because retina and auditory pathways can serve as measurable windows into early bioenergetic and organelle dysfunction in aging brains.
TMEM135 has reproducible links to systemic metabolic phenotypes (hepatic lipid handling, adipose energy balance, and stress adaptation).[4:2][5:3][12] Since metabolic syndrome and insulin resistance worsen risk trajectories in dementia and movement disorders, TMEM135 may be important in the metabolic amplification layer of neurodegeneration risk rather than as a direct trigger.[11:1][12:1]
Because of these gaps, TMEM135 should currently be framed as a mechanistic hypothesis node rather than a validated therapeutic target.
High-value next steps:
For NeuroWiki curation, TMEM135 is most useful when linked across:
This cross-link profile supports hypothesis generation for patient stratification, especially where metabolic burden and neurodegenerative progression overlap.
Zhou C, et al. TMEM135 links peroxisomes to the regulation of brown fat mitochondrial fission and energy homeostasis. Cell Death Differ. 2023. ↩︎ ↩︎ ↩︎ ↩︎
Nam H, et al. A mutation in Tmem135 causes progressive sensorineural hearing loss. Aging Cell. 2025. ↩︎ ↩︎ ↩︎ ↩︎
Exil VJ, et al. TMEM135 is a Novel Regulator of Mitochondrial Dynamics and Physiology with Implications for Human Health Conditions. Cells. 2021. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Zaveri A, et al. TMEM135 deficiency improves hepatic steatosis by suppressing CD36 in a SIRT1-dependent manner. Commun Biol. 2025. ↩︎ ↩︎ ↩︎
Zaveri A, et al. Transmembrane protein 135 regulates lipid homeostasis through its role in peroxisomal DHA metabolism. Cell Rep. 2023. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Passmore JB, et al. Peroxisomes and peroxisomal transketolase and transaldolase enzymes in the pathogenesis of Alzheimer's disease. Neurochem Res. 2008. ↩︎ ↩︎ ↩︎
Lee HJ, et al. Mouse Tmem135 mutation reveals a mechanism involving mitochondrial dynamics that leads to age-dependent retinal pathologies. Elife. 2016. ↩︎ ↩︎ ↩︎
Gao C, et al. Defective mitophagy in Alzheimer's disease. Mol Psychiatry. 2021. ↩︎ ↩︎
Giacomello M, et al. Mitochondrial Ca2+ as a key regulator of mitochondrial activities. Adv Exp Med Biol. 2017. ↩︎ ↩︎
Berger J, et al. Peroxisomes in brain development and function. Biochim Biophys Acta. 2013. ↩︎
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006. ↩︎ ↩︎
Arnold SE, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018. ↩︎ ↩︎